These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 33772528)

  • 41. Real-world dosing of omalizumab for chronic spontaneous urticaria.
    McIntyre AP; Viswanathan RK; Moss MH; Mathur SK
    Ann Allergy Asthma Immunol; 2020 Feb; 124(2):211-212. PubMed ID: 31805358
    [No Abstract]   [Full Text] [Related]  

  • 42. Safely use of omalizumab during SARS-CoV-2 infection in patients with chronic spontaneous urticaria.
    Özdemir Ö; Dikici Ü
    J Cosmet Dermatol; 2023 Jan; 22(1):26-27. PubMed ID: 36448319
    [No Abstract]   [Full Text] [Related]  

  • 43. A retrospective analysis omalizumab treatment patterns in patients with chronic spontaneous urticaria: a real-world study in Belgium.
    Lapeere H; Baeck M; Stockman A; Sabato V; Grosber M; Moutschen M; Lambert J; Vandebuerie L; de Montjoye L; Rabijns H; Allewaert K; Schrijvers R
    J Eur Acad Dermatol Venereol; 2020 Jan; 34(1):127-134. PubMed ID: 31099916
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Remission of chronic spontaneous urticaria following omalizumab with gradually extended dosing intervals: Real-life data.
    Salman A; Aktas M; Apti Sengun O
    Australas J Dermatol; 2021 Aug; 62(3):398-402. PubMed ID: 34156714
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Omalizumab Updosing in Chronic Spontaneous Urticaria: an Overview of Real-World Evidence.
    Metz M; Vadasz Z; Kocatürk E; Giménez-Arnau AM
    Clin Rev Allergy Immunol; 2020 Aug; 59(1):38-45. PubMed ID: 32418171
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Efficacy and Safety of Omalizumab (Xolair) for Cholinergic Urticaria in Patients Unresponsive to a Double Dose of Antihistamines: A Randomized Mixed Double-Blind and Open-Label Placebo-Controlled Clinical Trial.
    Gastaminza G; Azofra J; Nunez-Cordoba JM; Baeza ML; Echechipía S; Gaig P; García BE; Labrador-Horrillo M; Sala-Cunill A; Brescó MS; Beristain A; Quiñones D; Donado CD; Zubeldia JM; Ferrer M
    J Allergy Clin Immunol Pract; 2019; 7(5):1599-1609.e1. PubMed ID: 30654196
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Response of peripheral blood basophils in subjects with chronic spontaneous urticaria during treatment with omalizumab.
    MacGlashan D; Saini S; Schroeder JT
    J Allergy Clin Immunol; 2021 Jun; 147(6):2295-2304.e12. PubMed ID: 33716077
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Unique basophil microRNA signature in chronic spontaneous urticaria patients who respond to omalizumab.
    Al-Shaikhly T; MacDonald JW; Bammler TK; Altman MC; Ayars AG; Petroni DH; Tilles SA; Henderson WR
    Clin Exp Allergy; 2021 Dec; 51(12):1648-1652. PubMed ID: 34519110
    [No Abstract]   [Full Text] [Related]  

  • 49. Potential clinical and serological predictors of chronic spontaneous urticaria relapse in patients under omalizumab treatment.
    Grieco T; Dies L; Sernicola A; Chello C; Gagliostro N; Carnicelli G; Paolino G
    Immunotherapy; 2020 Nov; 12(16):1173-1181. PubMed ID: 32892673
    [No Abstract]   [Full Text] [Related]  

  • 50. Effect of omalizumab treatment on peripheral nerves in patients with chronic spontaneous urticaria.
    Altunisik E; Inan Dogan E
    Cutan Ocul Toxicol; 2021 Jun; 40(2):130-134. PubMed ID: 33902373
    [No Abstract]   [Full Text] [Related]  

  • 51. Omalizumab in chronic inducible urticaria: A retrospective, real-life study.
    Fialek M; Dezoteux F; Le Moing A; Karimova E; Ramdane N; Pape E; Azib-Meftah S; Staumont-Sallé D
    Ann Dermatol Venereol; 2021 Dec; 148(4):262-265. PubMed ID: 34247853
    [No Abstract]   [Full Text] [Related]  

  • 52. Case Report: Omalizumab for Chronic Spontaneous Urticaria in Pregnancy.
    Liao SL; Yu M; Zhao ZT; Maurer M
    Front Immunol; 2021; 12():652973. PubMed ID: 33796115
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Efficacy of additional treatment for chronic spontaneous urticaria refractory to treatment - A single-center retrospective real-world study.
    Ohata M; Oda Y; Washio K; Fukunaga A; Nishigori C
    J Dermatol; 2022 Jan; 49(1):e7-e8. PubMed ID: 34632611
    [No Abstract]   [Full Text] [Related]  

  • 54. Antihistamine-resistant chronic spontaneous urticaria remains undertreated: 2-year data from the AWARE study.
    Maurer M; Costa C; Gimenez Arnau A; Guillet G; Labrador-Horrillo M; Lapeere H; Meshkova R; Savic S; Chapman-Rothe N
    Clin Exp Allergy; 2020 Oct; 50(10):1166-1175. PubMed ID: 32735720
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [HOW PERIPHERAL BASOPHILS IN PATIENTS WITH CHRONIC SPONTANEOUS URTICARIA ARE CHANGED WITH OMALIZUMAB TREATMENT?].
    Oda Y; Washio K; Mizuno M; Imamura S; Nishigori C; Fukunaga A
    Arerugi; 2021; 70(9):1196-1199. PubMed ID: 34759084
    [No Abstract]   [Full Text] [Related]  

  • 56. Use of omalizumab in the treatment of chronic urticaria.
    Cordeiro Moreira AS; Rosmaninho Lopes de Soares E Silva MI; Pereira Guilherme MA; da Silva Ferreira JA; Fonseca Moreira da Silva JP
    Eur Ann Allergy Clin Immunol; 2016 Nov; 48(6):242-246. PubMed ID: 27852430
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Factors related to omalizumab resistance in chronic spontaneous urticaria.
    Magen E; Chikovani T; Waitman DA; Kahan NR
    Allergy Asthma Proc; 2019 Jul; 40(4):273-278. PubMed ID: 31262381
    [No Abstract]   [Full Text] [Related]  

  • 58. Chronic spontaneous urticaria treated with omalizumab: what differentiates early from late responders?
    Asero R
    Eur Ann Allergy Clin Immunol; 2021 Jan; 53(1):47-48. PubMed ID: 32378398
    [No Abstract]   [Full Text] [Related]  

  • 59. Omalizumab for severe chronic spontaneous urticaria: Real-life experiences of 280 patients.
    Vadasz Z; Tal Y; Rotem M; Shichter-Confino V; Mahlab-Guri K; Graif Y; Kessel A; Agmon-Levin N; Maoz-Segal R; Kivity S; Benor S; Lachover-Roth I; Zeldin Y; Stein M; Toker O; Hassoun G; Bezalel-Rosenberg S; Toubi E; Asher I; Sthoeger Z;
    J Allergy Clin Immunol Pract; 2017; 5(6):1743-1745. PubMed ID: 28988786
    [No Abstract]   [Full Text] [Related]  

  • 60. Multicentre experience of home omalizumab treatment for chronic spontaneous urticaria.
    Denman S; El-Shanaway T; Carne E; Devlin L; Savic S
    Eur J Hosp Pharm; 2020 Nov; 27(6):367-368. PubMed ID: 33097621
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.